1401. Inflliximab for Immune Reconstitution Inflammatory Syndrome (IRIS) in Tuberculous Meningitis: A Treatment Paradox
Ahad Azem, MBBS1; Faran Ahmad, MBBS2; Manasa Velagapudi, MBBS3; VA Nebraska Western Iowa Health Care System/Creighton University School of Medicine, Omaha, Nebraska; 2Creighton University School of Medicine, Omaha, Nebraska; 3CHI Health - Creighton University Medical Center - Bergan Mercy, Omaha, Nebraska

Methods. We report a case of paradoxical worsening of central nervous system TB after initiation of anti-TB medications, which was treated successfully with infliximab (IFX-a inhibitor).

Results. A 34-year-old man from Nepal with a history of untreated latent TB presented with complaints of occipital headache, slurred speech, and witnessed seizure. His physical exam was consistent with hyperreflexia. MRI of the brain revealed multiple small contrast-enhancing lesions in cerebral hemispheres. CT Chest showed bilateral centrilobular nodules suggestive of miliary TB. Cerebrospinal fluid (CSF) analysis showed pleocytosis, high protein, and low glucose. He was started on isoniazid, rifampin, ethambutol, and pyrazinamide along with high-dose dexamethasone for TB meningitis. Repeat MRI of the brain 6 months into therapy revealed worsening of brain lesions. Moxifloxacin and linezolid were added to the regimen given clinical progression on first-line therapy. 6 months into this enhanced regimen he started experiencing blurring of vision. Visual field mapping showed left visual field loss. IRIS from TB was suspected. Later, MTB DNA probe from bronchioalveolar lavage and CSF detected M. tuberculosis which was pan-susceptible. Repeat MRI of the brain 6 months into therapy showed new contrast-enhancing lesions. He was started on a second line regimen of linezolid exposure. All 16 patients with M. tuberculosis in initial sputa converted to negative culture results within 6 months of starting treatment. At 12 months after BPaL initiation, all patients had completed treatment, without TB recurrences or deaths reported.

Disclosures. All Authors: No reported disclosures

1402. NTM Infections: A Rising Global Health Problem/Clincial Characteristics and Outcomes of Patients with Non-Tuberculous Mycobacterial Infections at Two Tertiary Academic Medical Centers
AbdElhameed Nawwar, MD1; Julia Madrid-Morales, MD2; Carolina Velez-Mejia, MD3; Rigoberto De Jesus Pizarro, MD4; Victor Cepeda, MD5; Kelly R. Revelles, PharmD6; Felix A. Condeza-Zuluaga, MD6; Hait Javert, MD6; M. Velagapudi7; Universi ty of Texas Health Science Center at San Antonio, Texas, USA; San Antonio, Texas; Southern Illinois Healthcare (SIH), Herrin, Illinois; 5University of Texas at Austin, San Antonio, TX; 6University of Texas health and science center San Antonio, Audie L. Murphy VA Medical Center, San Antonio, Texas; UT Health San Antonio, San Antonio, Texas

Methods. We conducted a retrospective, multicenter review of patients with positive NTM cultures treated at University Hospital System and South Texas Veterans Health Care System (STVHCS) from 2011 to 2018. Infections were classified as pulmonary or extrapulmonary, and we recorded demographics, microbiological data, treatment regimens, duration, complications, follow-up and mortality. All categorical variables were described using percentages and compared between groups using the chi-square test.

Results. A total of 176 patients were included for analysis, of which 111 (63.1%) met criteria for NTM disease (2020 ATS/IDSA). The most common cultured mycobacterium was M. Avium Complex (MAC). M. abscessus-chelonae was more commonly associated with clinical disease and isolated from an extrapulmonary site whereas M. smegmatis complex was more commonly isolated in the sputum and cutaneous sites. Over 50% of patients received treatment (80% in the infected group). Cure was seen in 47.2%, all-cause mortality was 27% at last follow-up. Median duration of therapy was 10 months. 47% of patients experienced adverse effects which led to treatment discontinuation in one third of patients. Patients who were able to achieve a cure received a longer duration of therapy (12 vs 7 months; not statistically significant) and treatment was halted more commonly in the group that did not achieve eventual cure (42.6% vs. 16.7%, p=0.007).

Disclosures. All Authors: No reported disclosures

Table 1. Characteristics of patients overall (all culture positive patients) and by clinical infection

Table 2. Health outcomes of treated patients with clinical infection
Conclusion. NTM infections represent a therapeutic challenge with low cure rates and high mortality. An understanding of the risk factors, treatment options and outcomes is essential to guide appropriate management. Our study highlights high rates of adverse effects and discontinuation which precludes prolonged courses of therapy required to achieve cure.

Disclosures. All Authors: No reported disclosures

1403. Tuberculosis sacroiliitis: Clinical and Imaging Characteristics

Fatma Hammami, MD1; Makram Koubaa, MD1; Amal Chakroun, MD1; Chakib Marrakchi, MD1; Fatma Smoou, MD1; Mounir Ben Jemaa, MD1; Infectious Diseases Department, Hedi Chaker University Hospital, University of Sfax, Tunisia; Sfax, Sfax, Tunisia

Session: P-80. Tuberculosis and other Mycobacterial Infections

Background. Osteoarticular tuberculosis remains a common disease among which the spine is the most affected site. Less frequently, sacroiliac joint is involved. Its diagnosis is often delayed due to misleading and varied symptoms. The aim of this work was to study the clinical features and the contribution of imaging results in the diagnosis of tuberculous sacroiliitis.

Methods. We conducted a retrospective study including all patients hospitalized in the infectious disease department for tuberculous sacroiliitis. The diagnosis was based on clinical, laboratory and radiological features.

Results. In total, we encountered 12 women with a median age of 51 [39-63] years. Three patients had a family history of tuberculosis (25%). The median diagnostic delay was 155 [48-331] days. The revealing symptoms were low back pain (75%) and hip pain (25%) associated with fever (83.3%) and weight loss (75%). Reduced mobility was noted in 3 cases (25%). Pulmonary tuberculosis and tuberculosis spondylodiscitis were associated with tuberculous sacroiliitis in 5 cases (41.7%) and 4 cases (33.3%), respectively. Tuberculosis skin test was positive in 6 cases (50%). Laboratory investigations revealed elevated C-reactive protein levels in 11 cases (91.6%) and accelerated erythrocyte sedimentation rates in 9 cases (75%). Needle biopsy of the sacroiliac joint (41.7%) and soft tissues abscess puncture (16.6%) were performed. Computed tomography scan revealed joint space widening (83.3%), peripheral joint erosions (83.3%) and osteolysis (58.3%). Soft tissue abscesses were noted in 66.7% of the cases. Magnetic resonance imaging was performed in 4 cases (33.3%). Sacroiliac joint was hypointense in T1 weighted images (50%), hyperintense in T2 weighted images (50%) and in STIR images (50%). Bone scintigraphy, performed in 5 cases, revealed hyperfixation of the sacroiliac area (100%). All patients received antitubercular therapy. Percutaneous abscess drainage was indicated in 4 cases (33%).

Conclusion. Because of its deep localization, the diagnosis of tuberculous sacroiliitis is mainly based on imaging results associated with epidemiological, clinical and laboratory features. Antitubercular therapy initiated promptly leads to recovery.

Disclosures. All Authors: No reported disclosures

1404. Tuberculosis and HIV Coinfection: A Review of 135 Cases Experience of the Infectious Diseases Department-CHU: Mohamed VI- Marrakech

Zahid Talbi Alao1; Mohammed Raïtè, n/a1; Fatma Tabbane, n/a1; Nabila Sora, n/a1; Nouza Tassi, n/a1; Mohamed VI University hospital, infectious disease department, Marrakech, Marrakech-Tensift-El Haouz, Morocco; Mohamed VI University hospital, microbiology laboratory, Marrakech, Marrakech-Tensift-El Haouz, Morocco

Session: P-80. Tuberculosis and other Mycobacterial Infections

Background. Tuberculosis is a health problem in Morocco, which is increasingly indicative of human immunodeficiency virus (HIV) infection.

Objective. To determine the epidemiological, clinical and paraclinical, therapeutic and evocative aspects of tuberculosis and HIV co-infection.

Methods. We report 135 cases co-infected with HIV and tuberculosis, collected by the infectious diseases department at the Mohamed VI University Hospital in Marrakech. This is a 12-year retrospective study (2007 to 2020) that involved all HIV-infected patients hospitalized for tuberculosis regardless of its location.

Results. The mean age of the patients was 40 years (17-73 years). A male preponderance was noted in 69% of cases. In 74.6% of cases, tuberculosis was indicative of HIV infection. Nine patients were receiving antiretroviral (ARV) treatment at the time of the discovery of tuberculosis. There were 24% pulmonary tuberculosis, 25.3% extrapulmonary tuberculosis and 49% disseminated tuberculosis. Tuberculosis was confirmed in 31.7% of cases. At the time of tuberculosis diagnosis, the average CD4 count was 86 cells / mm. Quadruple therapy with isoniazid, rifampicin, pyrazinamide and ethambutol was started in 83% of patients. The average time to start ARVs was 7 weeks. All patients who received ARVs received a combination therapy comprising the combination of 2 nucleosides analog and one non-nucleoside analog. At the end of our work, the evolution was favorable in 53% of cases, death occurred in 25% of cases, 18.6% of patients were lost to follow-up, two cases of failure and another of relapse. Immune restoration syndrome was noted in 8 cases. Drug toxicity was observed in 24.5% of patients, 73% of which was related to hepatotoxicity of antibacterial drugs.

Conclusion. Tuberculosis is the most common opportunistic infection in people with HIV. Despite the advent of highly active triple therapy, tuberculosis is still a major cause of death in HIV positive people.

Disclosures. All Authors: No reported disclosures

1405. The Accuracy of Mycobacterium tuberculosis Specific IFN-γ/IL-2/TNF-α Fluorospot in Differential Diagnosis of Active Tuberculosis and Latent Tuberculosis Infection: A Case-Control Study

Lifan Zhang, n/a1; Huimin Ma, MD2; Qing Ge, Master3; Yueqiu Zhang, Bachelor4; Xiaochuan Shi, MD1; Qilei Cao, Bachelor5; Menggui Gao, Bachelor6; Xiaoqing Liu, Bachelor7; Peking Union Medical College Hospital, Beijing, Beijing, China; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China; Beijing Chest Hospital, Capital Medical University/Beijing, Beijing, Beijing, China; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Session: P-80. Tuberculosis and other Mycobacterial Infections

Background. To establish the Mycobacterium tuberculosis (MTB) specific IFN-γ/IL-2/TNF-α Fluorospot assay, and preliminarily evaluate its accuracy of differential diagnosis of active tuberculosis (ATB) and latent tuberculosis infection (LTBI).

Methods. Patients with pathologically confirmed and clinically diagnosed ATB in Peking Union Medical College Hospital and Beijing Chest Hospital from April 2020 to May 2021 were enrolled as case group, while patients with LTBI in the same period were enrolled as control group. The Fluorospot assay was used to simultaneously detect the secretion of IFN-γ, IL-2 and TNF-α T cells stimulated by the MTB specific antigens ESAT-6 and CFP-10 at the single-cell level. A binary logistic regression model was used to fit the combined diagnostic parameters, and the sensitivity, specificity, predictive value and likelihood ratio of the differential diagnosis of ATB and LTBI were calculated.

Table 5. Cure among patients treated with clinical infection

| Characteristic | Cure (n=42) | No Cure (n=47) | P-value |
|---------------|------------|---------------|---------|
| Age (years), median (IQR) | 62 (49-69) | 65 (56-72) | 0.2663 |
| Male sex (%), n/n | 39 (71.4) | 27 (57.4) | 0.1831 |
| Charlson index, median (IQR) | 4 (5-6) | 4 (5-6) | 0.4968 |
| Pulmonary source (%), n/n | 20 (59.0) | 35 (70.2) | 0.9052 |
| MAC, n/n | 14 (33.3) | 13 (27.7) | 0.9212 |
| Initial treatment % | 15 (34.9) | 16 (32.7) | 0.8496 |
| Macrolide/ethambutol/isoniazid | 39 (92.9) | 45 (97.9) | 0.9654 |
| Amikacin | 12 (28.6) | 15 (31.9) | 0.3712 |
| Interferon-gamma | 12 (28.6) | 16 (33.3) | 0.1016 |
| Cotrimoxazole | 1 (2.4) | 2 (4.2) | 0.997 |
| Imipramine | 1 (2.4) | 1 (2.1) | 0.9992 |
| Tegicline | 5 (11.9) | 21 (7.7) | 0.7003 |
| Linezolid | 1 (2.4) | 11 (23.4) | 0.0235 |
| Amikacin | 1 (2.4) | 1 (2.1) | 0.9992 |
| Treatment duration, median (IQR) | 13 (1-23) | 19 (14-19) | 0.3309 |
| Adherence | 22 (52.4) | 34 (74.5) | 0.0723 |
| Treatment halted, n/n | 7 (16.7) | 20 (42.6) | 0.0070 |

Figure 1: Schematic diagram of FluoroSpot (IFN-γ/IL-2/TNF-α) detecting cytokine-secreting specific T cells after stimulation with MTB specific antigen. A. The green spots are the total IFN-γ-secreting T cells; B. The red spots are the total IL-2-secreting T cells; C. The blue spots are the total TNF-α-secreting T cells; D. The green spots are the single IFN-γ-secreting T cells; the red spots are the single IL-2-secreting T cells; the blue spots are the single TNF-α-secreting T cells; the yellow spots are the dual IFN-γ/IL-2-secreting T cells; the cyan spots are the dual IFN-γ/TNF-α-secreting T cells; the purple spots are the dual IL-2/TNF-α-secreting T cells; the white spots are the triple IFN-γ/IL-2/TNF-α-secreting T cells.

Results. 62 patients with ATB (37 pathogen-confirmed ATB, 25 clinical diagnosed ATB), 87 patients with LTBI were included. There was significant correlation of the frequencies of total IFN-γ-secreting T cells detected by IFN-γ/IL-2/TNF-α Fluorospot assay compared with T-SPOT.TB after stimulation of MTB-specific antigen (r=0.829 for ESAT-6, P=0.001; r=0.804 for CFP-10, P=0.001). ROC curve was drawn for both T-SPOT.TB and Fluorospot. For T-SPOT.TB, the AUROC was 0.669 (95%CI 0.574-0.765), the sensitivity and specificity of differentiating ATB from LTBI are...